Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDEvoke Pharma, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Evoke Pharma, Inc. Earnings Date And Information
Evoke Pharma, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.94 earnings per share for the quarter, missing analysts' consensus estimates of $-0.38 by $0.56. The company had revenue of 2.65 M for the quarter and had revenue of 5.18 M for the year. Evoke Pharma, Inc. has generated $-28 earnings per share over the last year ($-27.97 diluted earnings per share) and currently has a price-to-earnings ratio of -0.84. Evoke Pharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Evoke Pharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.38 | -$0.94 | -0.56 | $3.36 M | $2.65 M |
| 08/13/2024 | Q2 2024 | -$0.72 | -$0.93 | -0.21 | $2.98 M | $2.55 M |
| 05/14/2024 | Q1 2024 | -$0.21 | -$2.09 | -1.88 | N/A | $1.74 M |
| 05/14/2024 | Q4 2023 | -$0.21 | -$7.13 | -6.92 | N/A | $1.68 M |
| 11/09/2023 | Q3 2023 | -$0.62 | -$6.08 | -5.46 | $1.26 M | $1.56 M |
| 08/10/2023 | Q2 2023 | -$0.73 | -$6.70 | -5.97 | $1.10 M | $1.13 M |
| 05/15/2023 | Q1 2023 | -$0.58 | -$8.81 | -8.23 | N/A | $810,408 |
| 03/21/2023 | Q4 2022 | $0.53 | -$6.36 | -6.89 | N/A | $796,370 |
| 11/09/2022 | Q3 2022 | -$0.66 | -$7.23 | -6.57 | $572,000 | $832,100 |
| 08/10/2022 | Q2 2022 | -$0.60 | -$8.47 | -7.87 | $580,000 | $461,795 |
| 05/10/2022 | Q1 2022 | -$5.77 | -$9.55 | -3.78 | N/A | $418,380 |
| 03/08/2022 | Q4 2021 | -$0.08 | -$7.37 | -7.29 | N/A | $360,571 |
| 11/10/2021 | Q3 2021 | -$0.07 | -$8.71 | -8.64 | $382,000 | $930,449 |
| 08/12/2021 | Q2 2021 | -$0.08 | -$10.19 | -10.11 | $151,000 | $236,635 |
| 05/12/2021 | Q1 2021 | -$8.65 | -$12.04 | -3.39 | N/A | $90,421 |
| 03/11/2021 | Q4 2020 | -$5.76 | -$12.27 | -6.51 | N/A | $23,020 |
| 11/10/2020 | Q3 2020 | -$14.41 | -$11.73 | 2.68 | N/A | $0 |
| 08/06/2020 | Q2 2020 | -$11.53 | -$40.15 | -28.62 | N/A | $0 |
| 05/12/2020 | Q1 2020 | -$7.21 | -$10.55 | -3.34 | N/A | $0 |
| 03/12/2020 | Q4 2019 | -$8.65 | -$8.40 | 0.25 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Evoke Pharma, Inc. Earnings: FAQ's
Evoke Pharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based offlast year's report dates.
The conference call for Evoke Pharma, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Evoke Pharma, Inc.'s latest earnings report can be read online.
Evoke Pharma, Inc. (:EVOK) has a recorded annual revenue of $5.18 M.
Evoke Pharma, Inc. (:EVOK) has a recorded net income of $-7,792,295.Evoke Pharma, Inc. has generated $-27.97 earnings per share over the last four quarters.
Evoke Pharma, Inc. (:EVOK) has a price-to-earnings ratio of -0.84 and price/earnings-to-growth ratio is -0.03.